Filter Results
:
(30)
Show Results For
-
All HBS Web
(115,592)
- Faculty Publications (30)
Show Results For
-
All HBS Web
(115,592)
- Faculty Publications (30)
←
Page 2 of
30
Results
- September 2020 (Revised January 2021)
- Case
Catalys Pacific
In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After...
View Details
Keywords:
Pharmaceutical Companies;
Biotech;
Health Care;
Entrepreneur;
Innovation;
International Business;
Entrepreneurial Finance;
Entrepreneurship;
Finance;
Innovation Strategy;
Venture Capital;
Strategy;
Cross-Cultural and Cross-Border Issues;
Pharmaceutical Industry;
Biotechnology Industry;
Tokyo
Krieger, Joshua Lev. "Catalys Pacific." Harvard Business School Case 821-035, September 2020. (Revised January 2021.)
- December 2019
- Case
Forecasting ClimaCell
By: Joshua Lev Krieger, Christopher Stanton and James Barnett
A weather technology startup, ClimaCell considers the R&D trade-offs and financing implications of pursuing a proposed contract with a major automobile maker, rather than continuing its focus on building a scalable, all-purpose weather prediction engine.
View Details
Keywords:
Weather;
Forecasting and Prediction;
Technological Innovation;
Research and Development;
Finance;
Cost vs Benefits;
Decision Making;
Strategy
Krieger, Joshua Lev, Christopher Stanton, and James Barnett. "Forecasting ClimaCell." Harvard Business School Case 820-044, December 2019.
- 2020
- Working Paper
Trials and Terminations: Learning from Competitors' R&D Failures
I analyze project continuation decisions where firms may resolve uncertainty through news about competitors' research and development (R&D) failures, as well as through their own results. I examine the trade-offs and interactions between product-market competition and...
View Details
Krieger, Joshua L. "Trials and Terminations: Learning from Competitors' R&D Failures." Harvard Business School Working Paper, No. 18-043, November 2017. (Revised June 2020. Forthcoming in Management Science.)
- November 2017
- Case
The 'Wonder Drug' That Killed Babies
By: Joshua Lev Krieger, Tom Nicholas and Matthew Preble
In the early 1960s, a popular drug taken by patients worldwide for a range of maladies was found to cause severe birth defects and other health problems in babies born to mothers who had taken it during a certain stage of fetal development. As many as 10,000 children...
View Details
Keywords:
Regulation;
Business and Government Relations;
Business and Community Relations;
Business and Stakeholder Relations;
Product Marketing;
Corporate Social Responsibility and Impact;
Business History;
Health;
Government Legislation;
Corporate Accountability;
Ethics;
Governing Rules, Regulations, and Reforms;
Pharmaceutical Industry;
Public Administration Industry;
United States;
United Kingdom;
Australia;
Germany;
Europe
Krieger, Joshua Lev, Tom Nicholas, and Matthew Preble. "The 'Wonder Drug' That Killed Babies." Harvard Business School Case 818-044, November 2017.
- Article
The Career Effects of Scandal: Evidence from Scientific Retractions
By: Pierre Azoulay, Alessandro Bonatti and Joshua Lev Krieger
We investigate how the scientific community's perception of a scientist's prior work changes when one of his articles is retracted. Relative to non-retracted control authors, faculty members who experience a retraction see the citation rate to their earlier,...
View Details
Azoulay, Pierre, Alessandro Bonatti, and Joshua Lev Krieger. "The Career Effects of Scandal: Evidence from Scientific Retractions." Research Policy 46, no. 9 (November 2017).
- Article
The Impact of Personal Genomics on Risk Perceptions and Medical Decision-Making
By: Joshua Lev Krieger, Fiona Murray, J. Scott Roberts and Robert C. Green
Krieger, Joshua Lev, Fiona Murray, J. Scott Roberts, and Robert C. Green. "The Impact of Personal Genomics on Risk Perceptions and Medical Decision-Making." Nature Biotechnology 34, no. 9 (September 2016): 912–918.
- Article
Retractions
By: Pierre Azoulay, Jeffrey L. Furman, Joshua Lev Krieger and Fiona Murray
Azoulay, Pierre, Jeffrey L. Furman, Joshua Lev Krieger, and Fiona Murray. "Retractions." Review of Economics and Statistics 97, no. 5 (December 2015): 1118–1136.
- Forthcoming
- Article
How Important Is Editorial Gatekeeping? Evidence from Top Biomedical Journals
We examine editors' influence on the scientific content of academic journals by unpacking the role of three major forces: journals' missions, aggregate supply of and demand for specific topics, and scientific homophily via editorial gatekeeping. In a sample of top...
View Details
Keywords:
Editors;
Biomedical Research;
Editorial Gatekeeping;
Scientific Homophily;
Intellectual Capital;
Mission and Purpose;
Journals and Magazines;
Intellectual Property;
Innovation and Invention;
Human Capital;
Higher Education;
Publishing Industry
Krieger, Joshua L., Kyle R. Myers, and Ariel D. Stern. "How Important Is Editorial Gatekeeping? Evidence from Top Biomedical Journals." Review of Economics and Statistics (forthcoming). (Pre-published online May 29, 2023.)
- Research Summary
Overview
In examining the competitive dynamics of R&D strategy, Josh has become particularly interested in how the introduction of new knowledge generated by rivals impacts the direction of R&D efforts. Understanding how new information alters project portfolio decisions is...
View Details
- Forthcoming
- Article
Standing on the Shoulders of Science
By: Joshua Lev Krieger, Monika Schnitzer and Martin Watzinger
Today’s innovations rely on scientific discoveries of the past, yet only some corporate
R&D builds directly on scientific output. In this paper, we analyze U.S. patents to
investigate how firms generate value by building on prior art “closer” to science. We
show...
View Details
Krieger, Joshua Lev, Monika Schnitzer, and Martin Watzinger. "Standing on the Shoulders of Science." Strategic Management Journal (forthcoming). (Pre-published online March 25, 2024.)